Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
By
randycupertino
Not artisan, but a perfectly fine bagel. Hits the spot.
Summary
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse models with obesity, independent of weight loss. The study shows reduced cartilage degeneration, osteophyte formation, synovial lesions, and pain sensitivity. The mechanism involves metabolic reprogramming of chondrocytes through the GLP-1R-AMPK-PFKFB3 signaling pathway, suggesting a novel therapeutic approach for obesity-related osteoarthritis.
Key quotes
· 4 pulledSemaglutide (SG), a glucagon-like peptide-1 receptor (GLP-1R) agonist, exhibits strong chondroprotective effects in an OA mouse model with obesity
These effects are independent of body weight loss and involve metabolic reprogramming of chondrocyte via the GLP-1R-AMPK-PFKFB3 signaling axis
Reduced pathological changes, including cartilage degeneration, osteophyte formation, synovial lesion, and pain sensitivity
Metabolic disorders have been recognized as a major contributor to the occurrence and progression of osteoarthritis (OA)
You might also wanna read
Study Compares Every-Third-Day vs Daily Low-Dose Aspirin Effects on Thromboxane Inhibition
This study compares the effectiveness of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in health
pubmed.ncbi.nlm.nih.gov·4mo ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·20m ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·32m agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·32m ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·9h ago
GeneSkin Develops mRNA Therapy Targeting Skin Stem Cells for Rejuvenation and Hair Growth
GeneSkin is developing a novel mRNA therapy targeting basal stem cells in the skin to address a wide range of dermatological issues includin
wyss.harvard.edu·11h ago